Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Q1 FY19 Earnings Presentation
20 slides from Jubilant Pharmova's earnings presentation, Jul 27, 2018
Slide 1: Financial Results Quarter Ended June 30, 2018
Financial Results Quarter Ended June 30, 2018
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : July, 27, 2018 Time : 05:00 pm IST + 91 22 6280 1141 Primary Number: + 91 22 7115 8042 +91-7045671221 Local Access Number: Available all over India. USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number: Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay from : Ju
Slide 4: Corporate Announcement
Corporate Announcement In our press release dated May 23, 2017, we had informed that Jubilant Pharma Limited (“JPL”), Singapore, a wholly- owned material subsidiary of the Company, in its board meeting had resolved that it will evaluate the option of fund raising by way of an Initial Public Offering
Slide 5: Q1'FY19 Results Analysis
JUBHANT LIFESCIENCES Q1’FY19 Results Analysis
Slide 6: Income Statement – Q1'FY19
Income Statement – Q1’FY19 Particulars Q1'FY18 Q1'FY19 YoY Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 1,556 2,079 34% Pharmaceuticals 811 1,181 46% Life Science Ingredients 700 847 21% Others (incl. Drug Disc. and India Branded Pharma) 45 51 11% Total Expenditure 1,219 1,641 3
Slide 7: Financial Highlights – Q1'FY19
Financial Highlights – Q1’FY19 • Consolidated revenue at Rs. 2,079 Crore, up 34% YoY • Pharmaceuticals revenue at Rs. 1,181 Crore, contributing 57% to revenue, up 46% YoY • Life Science Ingredients revenue at Rs. 847 Crore, contributing 41% to revenue, up 21% YoY • Others (incl. Drug Discovery Solut
Slide 8: Pharmaceuticals Business Highlights
Pharmaceuticals Business Highlights Revenue (Rs. Crs.) Revenue Analysis YoY Growth % Revenue Mix (%) Q1'FY18 Q1'FY19 Specialty Pharmaceuticals 469 816 74% 69% API & Generics 341 365 7% 31% Total 811 1,181 46% 100% EBITDA (Rs. Crs.) EBITDA Analysis YoY Growth % EBITDA Mix (%) Q1'FY18 Q1'FY19 Specialt
Slide 9: Region-wise Revenue - Pharmaceuticals Business
Region-wise Revenue - Pharmaceuticals Business Geo-wise Revenue (Rs crs) Q1'FY18 Q1'FY19 Mix % YoY % ROW International 778 1,159 98% 49% 6.9% Europe & India Japan 2.4% North America 610 985 83% 61% 7.8% Europe & Japan 102 93 8% -9% ROW 65 82 7% 25% North America India 33 28 2% -13% 82.9% Income from
Slide 10: Pharmaceuticals Business Highlights
Pharmaceuticals Business Highlights • Successful USFDA inspection of Jubilant Cadista and CMO Montreal facilities; Establishment Inspection Report (EIR) received for CMO Montreal • Started I-131 MIBG OPTIMUM Phase II Trials in July 2018 with two sites initiated • The information collected from this
Slide 11: Regulatory Status
Regulatory Status Regulatory Cadista Roorkee CMO / Allergy CMO JDI Montreal Nanjangud Agency USA India Spokane Montreal Canada India • All sites successfully inspected and fully Apr – May compliant with USFDA Mar 2017 Sep 2017 May 2018 Sep 2017 Oct 2017 (USA) 2018 regulations Apr 2018 Apr 2018 Oct 2
Slide 12: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Product pipeline as on June 30, 2018 Dosage (Orals) Sterile including JDI Region Total Filings Approval Pending Total Filings Approval Pending US 95 60 35 12 10 2 Canada 23 22 1 14 14 0 Europe 103 95 8 8 7 1 ROW 677 478 199 44 40 4 Total 898 655 243
Slide 13: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Dosage (Orals) Filed 95 ANDAs in the US i. 60 ANDAs have been approved and 35 ANDAs are pending approval ii. Filed 2 ANDAs in Q1’FY19; expect to file around 10 ANDAs during the year Made 803 filings in ROW markets including Canada, Europe and Jap
Slide 14: Region-wise Revenue – LSI Business
Region-wise Revenue – LSI Business Geo-wise Revenue (Rs crs) Q1'FY18 Q1'FY19 Mix % YoY % ROW International 312 305 36% -3% 10.3% Europe, North America and Japan 204 218 26% 7% Europe, North America and ROW 108 87 10% -20% Japan India 25.7% 64.0% India 388 542 64% 40% Income from Operations 700 847 1
Slide 15: LSI Business Highlights
LSI Business Highlights Specialty Intermediates: • New multipurpose Chlorinated Pyridine plant got commissioned in Q1’FY19 • On track for 6 new product launches in FY19; Commercialized one product and expect to commercialize the balance during the quarter Life Science Chemicals: • New Acetic Anhydri
Slide 16: Region-wise revenue - Others
Region-wise revenue - Others Geo-wise Revenue (Rs crs) Q1'FY18 Q1'FY19 Mix % YoY % ROW International 41 43 86% 6% 6.9% India Europe & 14.2% North America 30 30 59% 1% Japan Europe & Japan 10 10 19% -5% 19.4% ROW 1 3 7% 472% North America India 5 7 14% 57% 59.5% Income from Operations 45 51 100% 11%
Slide 17: Expenditure Analysis – Q1'FY19
Expenditure Analysis – Q1’FY19 YoY Growth Expenses (Rs Crs) Q1'FY18 % of Sales Q1'FY19 % of Sales % Material Cost and Change in Inventory 545 35% 737 35% 35% Purchases of stock-in-trade 38 2% 59 3% 55% Employee benefits expense 310 20% 452 22% 46% Power and fuel expense 90 6% 100 5% 10% Others 234 1
Slide 18: Debt Profile
Debt Profile Particulars 31/03/18 30/06/18 Foreign Currency Loans ($ Mn) ($ Mn) Standalone 9 9 Subsidiaries 358 358 Total 367 367 Rupee Loans (Rs. Crs) (Rs. Crs) Standalone 1,007 1,081 Subsidiaries 79 62 Total 1,086 1,142 Gross Debt (Rs. Crs) (Rs. Crs) Standalone 1,066 1,142 Subsidiaries 2,414 2,514
Slide 19: Outlook
Outlook We expect to deliver higher revenues and operating profits in FY19. The growth drivers for each of the business are expected to be as follows: • Specialty Pharmaceuticals: • New products and current contract execution in Radiopharmaceuticals is expected to drive growth • Addition of new ca
Slide 20: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 Ph: +91 22 6645 1209 E-mail: ravi.agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Gaurav Kashyap Jubilant Life Sciences Limited Perfect Relat
Jubilant Life Sciences — Q1 FY19 Earnings Presentation on 6ix